

Document Title: Blocks and Slides Archiving, retrieval and disposal

Document Number: TB SOP116

Staff involved in development:	Senior R&D Manager, Tissue Bank Team Leader, Tissue Bank Coordinators, Clinical Project Managers.			
Document author/owner:	Tissue Bank Team/Senior R&D Manager			
Directorate:	Research and Development			
Department:	Research and Development			
For use by:	Research Tissue Bank Staff			
Review due:	September 2028			

THIS IS A CONTROLLED DOCUMENT

Whilst this document may be printed, the electronic version maintained on the Trust's Intranet is the controlled copy. Any printed copies of this document are not controlled. ©Royal Papworth Hospital NHS Foundation Trust. Not to be reproduced without written permission.

Summary of Amendments

Version Number	Modification:
V1	Reviewed and updated SOP PRO/TE/TBR/017
V2	Reviewed and reference to RAC/RD/TBR/028 amended to RAC/RD/TBR/027
V3	Reviewed and updated to include Mesobank blocks and slides

	DN361 Biological Material for Research Use Policy
	DN001 Document Control Procedures
	Activity Location Guide
Key related documents:	DN375 Waste Management Policy
	Risk Assessments
	RAC/RDTBR/027 – Archiving blocks and slides



Key Points of this Document

1 Purpose and Contents

- a. This document defines the Trust's procedure for Blocks and Slides Archiving, Retrieval and Disposal.
- b. The research tissue banks and research team have their own block and slide storage units. See Tissue Bank Activity Location Guide.
- c. All tissue bank blocks and slides are stored in numerical order; each drawer is clearly labelled with the range of TB numbers held within.
- d. All Mesobank QC slides are organised in numerical order by bag barcode. Each drawer is clearly labelled to indicate the range of barcode numbers it contains. Tissue Micro Array (TMA) blocks and slides are stored according to their block numbers, with drawers clearly marked by TMA block number. Research blocks are arranged in numerical order based on sample barcodes, and each drawer is labelled to show the range of sample barcodes it holds.
- e. Research blocks and slides are labelled by the specific project number or title and filed in numerical order. On occasions they may be stored in separate drawers clearly labelled.
- f. Diagnostic blocks and slides are held on CUH premises for up to 3 years until transfer to offsite archive at Cellnass.

2 Roles & Responsibilities

- a. Staff involved in archiving and retrieving must comply with the requirements set out in Section 4.
- b. Training in this procedure will be by a competent member of the RPH research team.
- c. Following a period of supervision (depending on the individual needs of the trainee) there will be an informal assessment.



3 Policy

a. This SOP is mandatory and, as per the Trust's Information Governance and Records Management framework, non-compliance with it may result in disciplinary procedures.

4 Procedure

4.1 Archived Blocks & Slides

Tissue bank blocks and slides for RPH patients are filed in numerical case order and alphanumerical block suffix order (i.e. TB19.0001 A1-A4 followed by TB19.0050 A1-A10). When a valid tissue bank consent form is in place, tissue bank may use these diagnostic blocks and slides for tissue bank approved projects. A tissue bank number is generated by the database for tracking purposes, which will then be linked to the diagnostic block. They will be filed numerically in the tissue bank block store until the researcher(s) have confirmed they are happy with sections they have received, and that no more sections are required. Once we have received confirmation that all the sections are received, all diagnostic blocks and slides are to be returned to the diagnostic archive/laboratory.

Mesobank QC slides are filed in numerical order by bag barcode number, followed by alphanumeric tissue suffix (e.g., 400007829 A1, B1, B2, C1, D1, E1). Occasionally, Mesobank may provide diagnostic blocks, TMA blocks, and slides for specific REC-approved projects. Tracking is conducted using either project-specific spreadsheets or the TMA Master spreadsheet.

4.2 Archived Blocks & Slides retrieval

When blocks and slides are needed for projects, a location slip is completed and placed in the relevant location where blocks and/or slides have been removed from. The location slip should detail Block/Slide numbers removed, interim location, project number (if applicable) and date removed/initials of staff member for traceability.

If diagnostic blocks and slides are required from a Royal Papworth Hospital patient, and where a valid consent is in place, a member of the RPH research team will go over to the Cambridge University Hospitals Pathology archive and retrieve these for subsequent pathologist review and approval for use. Only blocks and slides up to 3 years old are kept on site, older ones are stored at CellNass, Wales.



For CellNass retrievals collate a list of diagnostic case numbers, including the specific suffix number if the whole case isn't required.

For pre 2019 samples - to order diagnostic blocks and slides from CellNass you must log a request through the CellNass website www.cellnass.com. Keep a record of the email request for billing purposes, making sure it is clearly labelled with the project number/researcher and date of request.

For 2019 onwards – the Tissue Bank team must make a request via CUH Pathology archive team, who will request the samples on RPH behalf.

4.3 Disposal of Research Blocks & Slides

For disposals in Royal Papworth Hospital, follow RPH waste disposal policy (DN375). For disposals in the HLRI follow the departmental Medicine Safety Manual. Complete tracking sheets/database to confirm disposal.

5 Risk Management / Liability / Monitoring & Audit

- a. The R&D SOP Committee will ensure that this SOP and any future changes to this document are adequately disseminated.
- b. The R&D Department will monitor adherence to this SOP via the routine audit and monitoring of individual clinical trials and the Trust's auditors will monitor this SOP as part of their audit of Research Governance. From time to time, the SOP may also be inspected by external regulatory agencies (e.g. Care Quality Commission, Medicines and Healthcare Regulatory Agency).
- c. In exceptional circumstances it might be necessary to deviate from this SOP for which written approval of the Senior R&D Manager should be gained before any action is taken. SOP deviations should be recorded including details of alternative procedures followed and filed in the Investigator and Sponsor Master File.
- d. The Research and Development Directorate is responsible for the ratification of this procedure.

Further Document Information

Approved by: Management/Clinical Dire Group	ectorate	Research and Development Directorate
Approval date: (this version)		Current approved version date



Ratified by Board of Directors/ Committee of the Board of Directors:			STET						
Date:			N/A						
This document supports: Standards and legislation			Medicines for Human Use (Clinical Trials) Regulations 2004 and all associated amendments UK Policy Framework for Health and Social Care Research version 3.3 (07/11/17) and authorised amendments thereafter						
Equality Impact Assessment: Does this document impact on any of the following groups? If YES, state positive or negative, complete Equality Impact Assessment Form available in Disability Equality Scheme document DN192 and attach.									
Groups	Disability	Race	Gender	Age	Sexual orientation	Religious & belief	Other		
Yes/No	NO	NO	NO	NO	NO	NO	NO		
Positive/Negative									
Review date:		September 2028							